Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b, Randomized, Open-label, Parallel-Group Study to Evaluate Different Dosing Regimens of Intravenous Efgartigimod to Maximize and Maintain Clinical Benefit in Patients With Generalized Myasthenia Gravis

NCT04980495 is registered in ClinicalTrials.gov with argenx as lead sponsor.

NCT NCT04980495
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04980495 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b, Randomized, Open-label, Parallel-Group Study to Evaluate Different Dosing Regimens of Intravenous Efgartigimod to Maximize and Maintain Clinical Benefit in Patients With Generalized Myasthenia Gravis
Lead sponsor
argenx
Phase
Phase 3
Overall status
Completed
Start date
December 16, 2021
Completion date
October 6, 2025
Enrollment
69 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

generalized myasthenia gravis, gmg, mg - myasthenia gravis